Treats hypertension. ANDA 76230, held by Prinston Pharmaceutical. Hydrochlorothiazide; Lisinopril.
As of Nov 21, 2026, ANDA 76230 (Lisinopril and Hydrochlorothiazide), held by Prinston Pharmaceutical, was first approved by FDA on Jul 1, 2002, with 3 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Lisinopril and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 1, 2002 | Original application | Approved | None posted |
| Lisinopril and Hydrochlorothiazide12.5MG;10MG · tablet;oral | Hydrochlorothiazide; Lisinopril | Rx |
| Lisinopril and Hydrochlorothiazide12.5MG;20MG · tablet;oral | Hydrochlorothiazide; Lisinopril | Rx |
| Lisinopril and Hydrochlorothiazide25MG;20MG · tablet;oral | Hydrochlorothiazide; Lisinopril | Rx |
| Aug 20, 2020 | Supplement 19Labeling · Standard review | Approved | None posted |
| Oct 20, 2004 | Supplement 5Labeling | Approved | None posted |
| May 13, 2003 | Supplement 2Labeling | Approved | None posted |
| Jul 1, 2002 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters